|
|
|
Insider
Information: |
Akkaraju Srinivas |
Relationship: |
|
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
19 |
|
Direct
Shares |
3,961,226 |
|
Indirect Shares
|
37,470,445 |
|
|
Direct
Value |
$19,702,089 |
|
|
Indirect Value
|
$276,102,231 |
|
|
Total
Shares |
41,431,671 |
|
|
Total
Value |
$295,804,320 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
5
|
3
|
Stock
price went up :
|
4
|
1
|
Stock
price went down : |
1
|
2
|
|
|
|
Gain/Loss Ratio : |
4.0
|
4.0
|
Percentage
Gain/Loss : |
28.4%
|
-84.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Pharmos Corp |
PARS |
Director |
|
0 |
2006-10-25 |
2,845,160 |
Premium* |
|
Seagen Inc |
SGEN |
Director |
2020-05-15 |
41,503 |
2008-09-22 |
600,559 |
Premium* |
|
Paratek Pharmaceuticals Inc |
PRTK |
Former 10% Beneficial ... |
2011-07-19 |
1,181,967 |
|
0 |
Premium* |
|
World Heart Corp |
WHRT |
10% Owner |
2012-08-02 |
0 |
2010-01-26 |
0 |
Premium* |
|
Icagen Inc |
ICGN |
|
2011-07-28 |
200,500 |
|
0 |
Premium* |
|
Synageva BioPharma Corp |
GEVA |
Former Director |
|
0 |
2012-06-27 |
1,026,832 |
Premium* |
|
Durata Therapeutics, Inc. |
DRTX |
10% Owner |
2012-07-24 |
0 |
2012-07-24 |
3,028,439 |
Premium* |
|
MEI Pharma Inc |
MEIP |
10% Owner |
2013-02-19 |
2,502,775 |
|
0 |
Premium* |
|
Zs Pharma, Inc. |
ZSPH |
Director |
2015-12-17 |
0 |
2014-06-23 |
609,455 |
Premium* |
|
aTyr Pharma Inc |
LIFE |
Former 10% Owner, Dire... |
2015-05-12 |
0 |
2015-05-12 |
1,866,126 |
Premium* |
|
Aravive Inc |
ARAV |
Director |
2019-12-02 |
31,815 |
2019-12-02 |
576,066 |
Premium* |
|
Syros Pharmaceuticals, Inc. |
SYRS |
Director |
2023-12-21 |
2,666 |
2023-12-21 |
1,786,427 |
Premium* |
|
Principia Biopharma Inc |
PRNB |
Director |
2018-09-18 |
0 |
2018-09-18 |
383,480 |
Premium* |
|
Chinook Therapeutics Inc |
KDNY |
Director |
2023-08-11 |
0 |
2023-08-11 |
0 |
Premium* |
|
Lenz Therapeutics |
LENZ |
10% Owner |
2021-06-29 |
0 |
2022-04-12 |
8,497,067 |
Premium* |
|
Scholar Rock Holding Corp |
SRRK |
Director, 10% Owner |
|
0 |
2023-10-16 |
6,788,609 |
Premium* |
|
Cargo Therapeutics, Inc. |
CRGX |
10% Owner |
|
0 |
2023-11-14 |
4,121,689 |
Premium* |
|
Mineralys Therapeutics, Inc. |
MLYS |
|
2024-02-12 |
0 |
2024-02-12 |
5,074,916 |
Premium* |
|
Vtv Therapeutics Inc. |
VTVT |
|
2024-02-27 |
0 |
2024-02-27 |
265,620 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
SGEN |
Seagen Inc |
Director |
|
2020-05-05 |
4 |
S |
$167.26 |
$1,421,710 |
D/D |
(8,500) |
40,168 |
0 |
% |
|
SGEN |
Seagen Inc |
Director |
|
2019-11-21 |
4 |
S |
$119.51 |
$2,096,120 |
D/D |
(17,500) |
40,168 |
0 |
- |
|
ZSPH |
Zs Pharma, Inc. |
Director |
|
2015-12-17 |
4 |
D |
$90.00 |
$90,000 |
D/D |
(1,000) |
0 |
0 |
- |
|
GEVA |
Synageva BioPharma Corp |
Former Director |
|
2012-06-26 |
4 |
S |
$40.16 |
$1,157,661 |
I/I |
(28,827) |
1,340,283 |
0 |
- |
|
GEVA |
Synageva BioPharma Corp |
Former Director |
|
2012-06-27 |
4 |
S |
$39.70 |
$12,444,005 |
I/I |
(313,451) |
1,026,832 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2013-05-10 |
4 |
S |
$37.17 |
$650,430 |
D/D |
(17,500) |
10,405 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2013-06-14 |
4 |
S |
$32.75 |
$163,750 |
D/D |
(5,000) |
13,905 |
0 |
- |
|
GEVA |
Synageva BioPharma Corp |
Director |
|
2012-03-19 |
4 |
S |
$32.55 |
$11,141,149 |
I/I |
(342,278) |
1,369,110 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2020-05-05 |
4 |
OE |
$20.06 |
$170,510 |
D/D |
8,500 |
48,668 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2019-11-21 |
4 |
OE |
$19.02 |
$332,850 |
D/D |
17,500 |
45,110 |
0 |
- |
|
PRNB |
Principia Biopharma Inc |
Director |
|
2018-09-18 |
4 |
B |
$17.00 |
$2,975,000 |
I/I |
175,000 |
383,480 |
2.1 |
- |
|
LENZ |
Lenz Therapeutics |
10% Owner |
|
2021-06-29 |
4 |
B |
$17.00 |
$8,500,000 |
I/I |
500,000 |
37,753 |
1.5 |
% |
|
CRGX |
Cargo Therapeutics, Inc. |
10% Owner |
|
2023-11-14 |
4 |
B |
$15.00 |
$9,999,990 |
I/I |
666,666 |
4,121,689 |
1.5 |
- |
|
LENZ |
Lenz Therapeutics |
10% Owner |
|
2021-10-07 |
4 |
B |
$14.94 |
$134,774 |
I/I |
9,021 |
7,464,366 |
1.5 |
% |
|
LIFE |
aTyr Pharma Inc |
Former 10% Owner |
|
2015-05-12 |
4 |
B |
$14.00 |
$4,480,000 |
I/I |
320,000 |
1,866,126 |
2.1 |
- |
|
KDNY |
Chinook Therapeutics Inc |
Director |
|
2021-11-15 |
4 |
B |
$14.00 |
$17,010,000 |
I/I |
1,215,000 |
4,591,888 |
2.1 |
% |
|
KDNY |
Chinook Therapeutics Inc |
Director |
|
2022-05-27 |
4 |
B |
$14.00 |
$7,980,000 |
I/I |
570,000 |
5,161,888 |
2.1 |
% |
|
LENZ |
Lenz Therapeutics |
10% Owner |
|
2021-10-06 |
4 |
B |
$13.83 |
$850,199 |
I/I |
61,475 |
7,455,345 |
1.5 |
% |
|
MLYS |
Mineralys Therapeutics, I... |
|
|
2024-02-12 |
4 |
A |
$13.50 |
$7,499,993 |
I/I |
555,555 |
5,074,916 |
0 |
- |
|
LENZ |
Lenz Therapeutics |
10% Owner |
|
2021-10-13 |
4 |
B |
$13.22 |
$600,188 |
I/I |
45,400 |
7,584,766 |
1.5 |
% |
|
LENZ |
Lenz Therapeutics |
10% Owner |
|
2021-10-08 |
4 |
B |
$13.12 |
$984,000 |
I/I |
75,000 |
7,539,366 |
1.5 |
% |
|
SYRS |
Syros Pharmaceuticals, In... |
Director |
|
2020-08-18 |
4 |
AS |
$13.10 |
$2,076,724 |
I/I |
(158,583) |
1,274,616 |
0 |
% |
|
SYRS |
Syros Pharmaceuticals, In... |
Director |
|
2020-08-17 |
4 |
AS |
$13.00 |
$9,672 |
I/I |
(744) |
1,433,199 |
0 |
% |
|
SGEN |
Seagen Inc |
Director |
|
2008-09-22 |
4 |
S |
$12.79 |
$237,907 |
I/I |
(18,601) |
600,559 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2013-05-10 |
4 |
OE |
$12.76 |
$223,300 |
D/D |
17,500 |
27,905 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|